Headquartered in Irvine, CA, USA, DNX was founded in 2014 and specializes in utilizing a cutting-edge technology called PASylation, licensed from XL-protein GmbH. This 21st-century platform extends the half-life of therapeutic proteins, allowing for more effective treatment of lifelong diseases. DNX holds a worldwide exclusive license to develop and commercialize several PASylated products. With a focus on auto-inflammatory diseases like rheumatoid arthritis, DNX aims to provide innovative solutions while offsetting development costs through the production of therapeutic proteins and biological drugs.